Aaron Wealth Advisors LLC Takes Position in Charles River Laboratories International, Inc. $CRL

Aaron Wealth Advisors LLC purchased a new position in Charles River Laboratories International, Inc. (NYSE:CRL) in the third quarter, Holdings Channel.com reports. The firm purchased 2,869 shares of the medical research company’s stock, valued at approximately $449,000.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in the stock. Brooklyn Investment Group boosted its holdings in Charles River Laboratories International by 93.5% in the first quarter. Brooklyn Investment Group now owns 178 shares of the medical research company’s stock worth $27,000 after purchasing an additional 86 shares during the last quarter. Cromwell Holdings LLC lifted its holdings in shares of Charles River Laboratories International by 542.9% during the 2nd quarter. Cromwell Holdings LLC now owns 180 shares of the medical research company’s stock valued at $27,000 after buying an additional 152 shares during the period. Neo Ivy Capital Management purchased a new position in shares of Charles River Laboratories International in the 2nd quarter worth $29,000. Geneos Wealth Management Inc. boosted its stake in shares of Charles River Laboratories International by 98.0% in the 2nd quarter. Geneos Wealth Management Inc. now owns 293 shares of the medical research company’s stock worth $44,000 after buying an additional 145 shares during the last quarter. Finally, Allworth Financial LP grew its holdings in shares of Charles River Laboratories International by 172.7% in the second quarter. Allworth Financial LP now owns 300 shares of the medical research company’s stock worth $45,000 after acquiring an additional 190 shares during the period. Institutional investors own 98.91% of the company’s stock.

Charles River Laboratories International Trading Down 1.1%

Shares of NYSE CRL opened at $193.76 on Friday. Charles River Laboratories International, Inc. has a fifty-two week low of $91.86 and a fifty-two week high of $200.58. The company has a market cap of $9.54 billion, a price-to-earnings ratio of -124.21, a PEG ratio of 6.92 and a beta of 1.63. The business’s 50 day moving average price is $179.24 and its 200-day moving average price is $164.93. The company has a debt-to-equity ratio of 0.64, a quick ratio of 1.10 and a current ratio of 1.37.

Charles River Laboratories International (NYSE:CRL) last posted its quarterly earnings results on Wednesday, November 5th. The medical research company reported $2.43 EPS for the quarter, topping analysts’ consensus estimates of $2.32 by $0.11. The firm had revenue of $1 billion for the quarter, compared to analysts’ expectations of $990.43 million. Charles River Laboratories International had a negative net margin of 2.07% and a positive return on equity of 15.78%. The business’s revenue for the quarter was down .5% on a year-over-year basis. During the same period in the prior year, the business posted $2.59 earnings per share. On average, sell-side analysts expect that Charles River Laboratories International, Inc. will post 9.36 earnings per share for the current year.

Analyst Ratings Changes

A number of research firms have weighed in on CRL. Evercore ISI increased their target price on Charles River Laboratories International from $190.00 to $200.00 and gave the company an “outperform” rating in a report on Friday, October 3rd. Wall Street Zen cut Charles River Laboratories International from a “buy” rating to a “hold” rating in a research report on Saturday, December 13th. Argus set a $200.00 price objective on shares of Charles River Laboratories International in a research report on Monday, November 17th. Robert W. Baird raised Charles River Laboratories International from a “neutral” rating to an “outperform” rating and boosted their price target for the stock from $178.00 to $199.00 in a report on Thursday, November 6th. Finally, Bank of America raised shares of Charles River Laboratories International from a “neutral” rating to a “buy” rating and set a $225.00 price objective for the company in a report on Monday. One analyst has rated the stock with a Strong Buy rating, eleven have assigned a Buy rating, five have issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $195.93.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).